The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! About 751,118 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 26.58% since April 13, 2016 and is uptrending. It has outperformed by 22.65% the S&P500.
The move comes after 9 months positive chart setup for the $1.20 billion company. It was reported on Nov, 15 by Barchart.com. We have $53.78 PT which if reached, will make NYSE:PBYI worth $372.00 million more.
Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage
Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Citigroup upgraded the shares of PBYI in a report on Monday, December 14 to “Buy” rating. JP Morgan maintained the shares of PBYI in a report on Tuesday, March 29 with “Overweight” rating. UBS maintained it with “Buy” rating and $60 target price in Monday, April 11 report. On Tuesday, March 29 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. Credit Suisse maintained Puma Biotechnology Inc (NYSE:PBYI) on Tuesday, March 29 with “Outperform” rating. The stock has “Buy” rating given by Citigroup on Tuesday, March 29. The stock of Puma Biotechnology Inc (NYSE:PBYI) earned “Buy” rating by Stifel Nicolaus on Wednesday, September 21. Citigroup initiated the stock with “Neutral” rating in Thursday, September 3 report. The rating was initiated by JP Morgan on Thursday, August 27 with “Overweight”. The rating was maintained by Credit Suisse with “Outperform” on Thursday, September 22.
According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”
Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.18, from 1.03 in 2016Q1. The ratio increased, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Moreover, Natl Bank Of America Corporation De has 0% invested in Puma Biotechnology Inc (NYSE:PBYI) for 266,479 shares. Wells Fargo & Mn holds 8,700 shares or 0% of its portfolio. Checchi Advisers holds 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 101 shares. Tourbillon Capital Prtnrs Lp has 587,126 shares for 0.35% of their US portfolio. Rhumbline Advisers accumulated 27,358 shares or 0% of the stock. Weatherbie Cap Limited Liability owns 280,985 shares or 1.19% of their US portfolio. Blackrock Grp Incorporated Limited last reported 0% of its portfolio in the stock. State Street Corp reported 1.06M shares or 0% of all its holdings. Retail Bank Of New York Mellon, a New York-based fund reported 111,918 shares. Fiera Cap has 0% invested in the company for 7,800 shares. Huntington Natl Bank has 0% invested in the company for 7 shares. Canada Pension Plan Inv Board last reported 10,900 shares in the company. Profund Advsrs Ltd Liability Com, a Maryland-based fund reported 12,706 shares. Glob X Mngmt Communication Ltd has 142 shares for 0% of their US portfolio. Voya Investment Mngmt Ltd Limited Liability Company owns 10,633 shares or 0% of their US portfolio.
More notable recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Investorplace.com which released: “Why Dynavax Technologies Corporation (DVAX), Petroleo Brasileiro SA Petrobras …” on November 14, 2016, also Fool.com with their article: “Why Puma Biotechnology Inc. Sold Lower Today” published on October 19, 2016, Businesswire.com published: “Puma Biotechnology Announces Presentations of Investigational Data at the San …” on November 15, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) were released by: Nasdaq.com and their article: “January 2019 Options Now Available For Puma Biotechnology (PBYI)” published on November 14, 2016 as well as Prnewswire.com‘s news article titled: “Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick …” with publication date: November 09, 2016.
PBYI Company Profile
Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.